Skip to navigation Skip to content

Chronic myelomonocytic leukaemia program in Pharmaceutical Benefits Scheme (PBS) 012-22062453

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised azacitidine and decitabine+cedazuridine for patients with chronic myelomonocytic leukaemia (CMML).

For details on how to process a PBS Authority, see Processing Complex Authority Required Listings.

Chronic myelomonocytic leukaemia quick reference

Restrictions

Authority level and section

PA assessment

Processing system

Prescriber type

Prescriber self-serve

Initial

PB079 form

Written

Electronic

S100:

Azacitidine

No

OPA

N/A

Yes

Initial

PB340 form

Written

Electronic

S85:

Decitabine+ cedazuridine

(general listing)

No

OPA

N/A

Yes

Continuing

Telephone

Electronic

S100:

Azacitidine

S85:

Decitabine+ cedazuridine

(general listing)

No

OPA

N/A

Yes